Razan Awan: Large Cohort Study Questions Routine Use of Dual Antiplatelet Therapy After TAVI
ٌRazan Awan, Deputy Director of Residency Training Program at King Fahd Armed Forces Hospital, Cardiology Clinical Pharmacy Specialist, shared a post on LinkedIn about a recent article she and her colleagues co-authored, published in Journal of Clinical Medicine, adding:
“Our new paper has just been published!
‘Single Versus Dual Antiplatelet Therapy After Transcatheter Aortic Valve Implantation in Patients Without Chronic Anticoagulation.’
Journal of Clinical Medicine — Published June 5, 2026
In this work, we analyzed 662 consecutive TAVI patients without chronic anticoagulation to compare single antiplatelet therapy (SAPT) versus dual antiplatelet therapy (DAPT).
Across multiple analytical models — including time-varying, intention-to-treat, landmark, and IPTW-weighted Cox analyses — no statistically significant difference was found between SAPT and DAPT in ischemic MACE (death, stroke, or MI) or net adverse clinical events.
These real-world findings support SAPT as a reasonable default antiplatelet strategy after TAVI, consistent with current ACC/AHA and ESC guidelines.
A special thank you to our lead author Monirah Albabtain, and corresponding author Amr Arafat, and to all co-authors for their incredible collaboration and dedication: Aisha Alrasheedi, Maha M. AlHarthi, Zaid Alanazi, and Nawaf Aldhubayti.”
Title: Single Versus Dual Antiplatelet Therapy After Transcatheter Aortic Valve Implantation in Patients Without Chronic Anticoagulation
Authors: Monirah A. Albabtain, Aisha Alrasheedi, Razan M. Awan, Maha Alharthi, Zaid Alanazi, Nawaf Aldhubayti, Amr A. Arafat
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 15, 2026, 01:37Lesley Van Wyk: Exploring Sickle Cell Disease – The HbS Story
-
Sep 15, 2026, 01:31Luca Seffin: To the Science, the People, and the Journey – Thank You SR-Tiget
-
Sep 14, 2026, 23:49Heghine Khachatryan: New evidance – Antiphospholipid Antibodies and Ischemic Stroke
-
Sep 14, 2026, 23:42Eman M. Elsabbagh: Successful HCT Does Not End at Engraftment
-
Sep 14, 2026, 23:31Antonis Kattamis: Proud to Be Part of this Endeavour and Senior Author of the Pivotal Trial
-
Sep 14, 2026, 23:23Farjah Algahtani: Stroke Incidence and Risk Factors in Saudi Patients with Sickle Cell Disease
-
Sep 14, 2026, 20:53YoonHwa An: Rusfertide in Polycythemia Vera – From Clinical Benefit to Strategic Value
-
Sep 14, 2026, 20:52Andres Alberto Mercado Pompa: External Validation of Prognostic Risk Scores in Cerebral Venous Thrombosis
-
Sep 14, 2026, 20:50Balaji Kirushnan: Advancing Regional Citrate Anticoagulation in CRRT – From Experience to Implementation